Share on facebook
Share on twitter
Share on linkedin
Share on telegram
Share on whatsapp

Vaccine-Resistant Mutations Strongly Correlate With COVID-19 Vaccination Rates, Study Finds

Share on facebook
Share on twitter
Share on telegram
Share on email
Share on print

A team of researchers from Michigan State University have made a bombshell discovery about vaccine-resistant variants of SARS-CoV-2. The preprint study is awaiting peer-review and will be published in American Chemical Society.


By tracking the evolutionary trajectories of COVID-19 vaccine-resistant mutations in more than 2.2 million SARS-CoV-2 genomes, data revealed that the occurrence and frequency of these vaccine-resistant mutations correlate strongly with the COVID-19 vaccination rates in Europe and America.

“We anticipate that as a complementary transmission pathway, vaccine-resistant mutations will become a dominating mechanism of SARS-CoV-2 evolution when most of the world’s population is vaccinated,” the authors concluded.

“The importance of understanding SARS-CoV-2 evolution cannot be overemphasized.”

It sounds a lot like what Dr. Geert Vanden Bossche warned would happen billions and billions of doses ago. The fact that many separate lineages of SARS-CoV-2 appear to all be converging on the same specific mutations—such as Y449S and Y449H—suggests the virus is stumbling through random mutations until it finds effective solutions to highly vaccinated populations. When mutations that escape COVID-19 vaccine protection are free to dominate, variants that cannot escape fail to compete and eventually go extinct.

Article by Dr. Geert Vanden Bossche published on Dec 7, 2021

Back in July 2021, many scientists had the ill-founded view that the C-19 pandemic was dying out and entering an endemic state. Based on my understanding of the interplay between the virus and the immune system, I knew that this was not going to be the case and reacted immediately to this misinterpretation ( Once again, many scientists find themselves with the belief that the emergence of the Omicron variant announces the end of the pandemic and the virus’ transition into endemicity. Their prediction is largely based upon the initial observation that Omicron seems to be causing rather mild disease symptoms which they interpret as being indicative of a virus that—although more infectious—is now becoming less virulent and, therefore, increasingly featuring endemic behavior. I am afraid that once again, I don’t agree—a pandemic can only be tamed by herd immunity. Given the high vaccine coverage rates in most industrialized countries, we have generated anything but herd immunity. I also have yet to hear any compelling evidence concerning significant mutations in the genes that determine SARS-CoV-2’s virulence. Perhaps we should think twice before making statements that are not supported by immunological evidence.

This is what I believe is currently happening.

As Omicron appears largely resistant to neutralizing antibodies (Abs), it no longer strongly binds to vaccinal Abs (still directed at the spike protein [S] of the Wuhan strain). More specifically, Omicron allows for the restoring of full functional capacity of relevant innate Abs. The latter are known to be very efficient in preventing or abrogating productive infection and, therefore, preventing (severe) disease in individuals endowed with an intact innate immune system (i.e., people in good health and without underlying diseases or immune suppression, including vaccine-mediated immune suppression). As vaccinal neutralizing Abs are highly specific, they are less likely to bind to the receptor-binding domain (RBD) of Omicron, which has undergone a multitude of mutations within this very domain. It is, therefore, reasonable to expect that the vaccine-mediated Abs will fail to outcompete relevant innate Abs in vaccinees and hence, increase the incidence of asymptomatic infections in this population. It is intriguing that the Israeli Ministry of Health interprets asymptomatic infection in vaccinees as proof of “full protection” despite the fact that Omicron is highly suspicious of bypassing neutralizing antibodies (1, 2). Asymptomatic disease is known to lead to a short duration of anti-S Ab titers (3, 4). However, due to the high level of infectivity of Omicron, re-exposure to the virus is highly likely to occur with a timeframe that is short enough to coincide with elevated anti-S Ab levels. Consequently, dominant circulation of Omicron would ultimately make vaccinees more frequently susceptible to disease, whereas fewer and fewer unvaccinated individuals would be susceptible to contracting C-19 disease as a result of innate immune training upon viral exposure. In conclusion, it seems highly unlikely that dominant circulation of Omicron will result in diminished incidence of disease and cause the pandemic to transition into an endemic state. In contrast to the situation in the pre-Omicron era, the incidence of disease is now likely to disproportionately increase in vaccinees. This may, once again, prompt public health authorities to follow the erroneous advice of the vaccine industry and key opinion leaders who will undoubtedly recommend to continue the mass vaccination program using updated vaccines that suit the S version of the Omicron variant. In a previous contribution, I’d already predicted the dire consequences such a decision would entail (—in brief, it will allow the virus to make a natural selection favoring hosts who preserved a fully functional innate immune defense.



Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x

Get in Touch!

Purpose of your Contact
Where can i reach you?
What would you like to discuss?

Are you intending to visit the Lorphic marketing agency?